<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Karamitros, T.</style></author><author><style face="normal" font="default" size="100%">Kakkanas, A.</style></author><author><style face="normal" font="default" size="100%">Katsoulidou, A</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Dalagiorgou, G.</style></author><author><style face="normal" font="default" size="100%">Mavromara, P.</style></author><author><style face="normal" font="default" size="100%">Hatzakis, A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin</style></title><secondary-title><style face="normal" font="default" size="100%">J Viral HepatJ Viral HepatJ Viral Hepat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of viral hepatitis</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of viral hepatitisJournal of viral hepatitis</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiviral Agents/therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Escherichia coli/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepacivirus/immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C Antibodies/*blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis C, Chronic/drug therapy/*immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Interferon-alpha/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Polyethylene Glycols/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Recombinant Proteins/biosynthesis/genetics/immunology/therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">Ribavirin/*therapeutic use</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Viral/blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Core Proteins/genetics/*immunology</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">182-8</style></pages><isbn><style face="normal" font="default" size="100%">1365-2893 (Electronic)1352-0504 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Hepatitis C virus (HCV) infection is a major cause for chronic liver disease and hepatocellular carcinoma. The HCV-ARF/core+1 protein is an alternative product of HCV core-encoding sequence of unknown biological function. Highly purified HCV core and ARF/core+1 recombinant proteins from HCV genotype 1a and HCV-ARF/core+1 recombinant protein from HCV genotype 3a were expressed in Escherichia coli. Using an enzyme-linked immunosorbent assay, we assessed the prevalence of anti-ARF/core+1 antibodies in 90 chronic hepatitis C patients infected with HCV genotypes 1a/1b or 3a, treated with pegylated interferon (Peg-IFN-a-2a) plus ribavirin. Samples derived from 92 healthy blood donors were used as negative controls. All HCV-RNA-positive serum samples reacted with core 1a antigen, while 15 (37.5%) of 40 and 14 (28%) of 50 patients infected with HCV-1a/1b and HCV-3a, respectively, were found to have anti-ARF/core+1 antibodies into their serum before treatment initiation. These antibodies were persistently present during treatment follow-up and linked to elevated levels of HCV-RNA at baseline.</style></abstract><accession-num><style face="normal" font="default" size="100%">22329372</style></accession-num><notes><style face="normal" font="default" size="100%">Karamitros, TKakkanas, AKatsoulidou, ASypsa, VDalagiorgou, GMavromara, PHatzakis, AengResearch Support, Non-U.S. Gov'tEngland2012/02/15 06:00J Viral Hepat. 2012 Mar;19(3):182-8. doi: 10.1111/j.1365-2893.2011.01502.x. Epub 2011 Oct 4.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece.</style></auth-address></record></records></xml>